126 related articles for article (PubMed ID: 15570930)
1. [Infection control in neutropenia induced by high-dose cytarabine chemotherapy].
Miyazaki M; Senzaki K; Kiyoi H; Kohno S; Noda Y; Nabeshima T
Gan To Kagaku Ryoho; 2004 Nov; 31(12):2011-5. PubMed ID: 15570930
[TBL] [Abstract][Full Text] [Related]
2. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study.
Weick JK; Kopecky KJ; Appelbaum FR; Head DR; Kingsbury LL; Balcerzak SP; Bickers JN; Hynes HE; Welborn JL; Simon SR; Grever M
Blood; 1996 Oct; 88(8):2841-51. PubMed ID: 8874180
[TBL] [Abstract][Full Text] [Related]
3. Comparison of neutropenia profiles in different treatment protocols for acute myeloid leukemia using the D-index.
Kawasaki Y; Kimura SI; Nakano H; Mashima K; Shirato Y; Kawaguchi SI; Toda Y; Ochi SI; Nagayama T; Minakata D; Yamasaki R; Morita K; Ashizawa M; Yamamoto C; Hatano K; Sato K; Oh I; Fujiwara SI; Ohmine K; Kako S; Muroi K; Kanda Y
Int J Hematol; 2019 Apr; 109(4):470-476. PubMed ID: 30684252
[TBL] [Abstract][Full Text] [Related]
4. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98.
Creutzig U; Zimmermann M; Lehrnbecher T; Graf N; Hermann J; Niemeyer CM; Reiter A; Ritter J; Dworzak M; Stary J; Reinhardt D
J Clin Oncol; 2006 Sep; 24(27):4499-506. PubMed ID: 16983120
[TBL] [Abstract][Full Text] [Related]
5. A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan Adult Leukemia Study Group AML 97 Study.
Miyawaki S; Sakamaki H; Ohtake S; Emi N; Yagasaki F; Mitani K; Matsuda S; Kishimoto Y; Miyazaki Y; Asou N; Matsushima T; Takahashi M; Ogawa Y; Honda S; Ohno R;
Cancer; 2005 Dec; 104(12):2726-34. PubMed ID: 16284985
[TBL] [Abstract][Full Text] [Related]
6. Infectious complications in patients with acute myeloid leukemia treated according to the protocol with daunorubicin and cytarabine with or without addition of cladribine. A multicenter study by the Polish Adult Leukemia Group (PALG).
Lech-Maranda E; Seweryn M; Giebel S; Holowiecki J; Piatkowska-Jakubas B; Wegrzyn J; Skotnicki A; Kielbinski M; Kuliczkowski K; Paluszewska M; Jedrzejczak WW; Dutka M; Hellmann A; Flont M; Zdziarska B; Palynyczko G; Konopka L; Szpila T; Gawronski K; Sulek K; Sokolowski J; Kloczko J; Warzocha K; Robak T
Int J Infect Dis; 2010 Feb; 14(2):e132-40. PubMed ID: 19581118
[TBL] [Abstract][Full Text] [Related]
7. Phase II evaluation of an intensified induction therapy with standard daunomycin and cytarabine followed by high dose cytarabine for adults with previously untreated acute myeloid leukemia: a Southwest Oncology Group study (SWOG-9500).
Petersdorf SH; Rankin C; Head DR; Terebelo HR; Willman CL; Balcerzak SP; Karnad AB; Dakhil SR; Appelbaum FR
Am J Hematol; 2007 Dec; 82(12):1056-62. PubMed ID: 17696203
[TBL] [Abstract][Full Text] [Related]
8. Minimal residual disease as biomarker for optimal biologic dosing of ARA-C in patients with acute myeloid leukemia.
Maurillo L; Buccisano F; Piciocchi A; Del Principe MI; Sarlo C; Di Veroli A; Panetta P; Irno-Consalvo M; Nasso D; Ditto C; Refrigeri M; De Angelis G; Cerretti R; Arcese W; Sconocchia G; Lo-Coco F; Amadori S; Venditti A
Am J Hematol; 2015 Feb; 90(2):125-31. PubMed ID: 25377359
[TBL] [Abstract][Full Text] [Related]
9. Daunorubicin, cytarabine and fludarabine (DAF) for remission induction in relapsed or refractory acute myeloid leukemia. Evaluation of safety, tolerance and early outcome--Polish Adult Leukemia Group (PALG) pilot study.
Hołowiecki J; Grosicki S; Kyrcz-Krzemien S; Skotnicki AB; Piatkowska-Jakubas B; Warzocha K; Seferynska I; Zdziarska B
Ann Hematol; 2008 May; 87(5):361-7. PubMed ID: 18074133
[TBL] [Abstract][Full Text] [Related]
10. [Prophylaxis with ciprofloxacin in postchemotherapy neutropenia in acute myeloid leukemia].
López A; Soler JA; Juliá A; Novo A; Bueno J
Med Clin (Barc); 1994 Jan; 102(3):81-5. PubMed ID: 8133717
[TBL] [Abstract][Full Text] [Related]
11. Acute myeloid leukemia in Manitoba. The consequences of standard "7 + 3" remission-induction therapy followed by high dose cytarabine postremission consolidation for myelosuppression, infectious morbidity, and outcome.
Bow EJ; Kilpatrick MG; Scott BA; Clinch JJ; Cheang MS
Cancer; 1994 Jul; 74(1):52-60. PubMed ID: 8004583
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of subcutaneous recombinant human interleukin 11 with subcutaneous recombinant human granulocyte-macrophage colony stimulating factor in patients with acute myeloid leukemia (AML) receiving high-dose cytarabine during induction: ECOG 3997.
Cripe LD; Rader K; Tallman MS; Gordon MS; Paietta E; Bennett J; Neuberg D; Litzow MR; O'brien TE; Rowe JM
Leuk Res; 2006 Jul; 30(7):823-7. PubMed ID: 16413056
[TBL] [Abstract][Full Text] [Related]
13. Combination chemotherapy with low-dose cytarabine, homoharringtonine, and granulocyte colony-stimulating factor priming in patients with relapsed or refractory acute myeloid leukemia.
Zhang WG; Wang FX; Chen YX; Cao XM; He AL; Liu J; Ma XR; Zhao WH; Liu SH; Wang JL
Am J Hematol; 2008 Mar; 83(3):185-8. PubMed ID: 17899614
[TBL] [Abstract][Full Text] [Related]
14. [Fluoroquinolone prophylaxis utility during chemotherapy-induced severe neutropenia in patients with acute leukemia, with fluoroquinolone resistance high prevalence, in a reference hospital in Mexico City].
Ugarte-Torres A; Villasis-Keever A; Hernández-Bribiesca ME; Crespo-Solis E; Ruiz-Palacios GM; Sifuentes-Osornio J; Ponce-De-León-Garduño A
Rev Invest Clin; 2006; 58(6):547-54. PubMed ID: 17432285
[TBL] [Abstract][Full Text] [Related]
15. Post-remission therapy of adult acute myeloid leukaemia: one cycle of high-dose versus standard-dose cytarabine. Leukaemia Project Group of the Swiss Group for Clinical Cancer Research (SAKK).
Fopp M; Fey MF; Bacchi M; Cavalli F; Gmuer J; Jacky E; Schmid L; Tichelli A; Tobler A; Tschopp L; Von Fliedner V; Gratwohl A
Ann Oncol; 1997 Mar; 8(3):251-7. PubMed ID: 9137794
[TBL] [Abstract][Full Text] [Related]
16. Sequential continuous infusion of fludarabine and cytarabine associated with liposomal daunorubicin (DaunoXome) (FLAD) in primary refractory or relapsed adult acute myeloid leukemia patients.
Camera A; Rinaldi CR; Palmieri S; Cantore N; Mele G; Mettivier V; Miraglia E; Mastrullo L; Grimaldi F; Luciano L; Guerriero A; Rotoli B; Ferrara F
Ann Hematol; 2009 Feb; 88(2):151-8. PubMed ID: 18709502
[TBL] [Abstract][Full Text] [Related]
17. High frequency of streptococcal bacteraemia during childhood AML therapy irrespective of dose of cytarabine.
Johannsen KH; Handrup MM; Lausen B; Schrøder H; Hasle H
Pediatr Blood Cancer; 2013 Jul; 60(7):1154-60. PubMed ID: 23281248
[TBL] [Abstract][Full Text] [Related]
18. Assessment of febrile neutropenia episodes in children with acute leukemia treated with BFM protocols.
Yilmaz S; Oren H; Demircioğlu F; Irken G
Pediatr Hematol Oncol; 2008; 25(3):195-204. PubMed ID: 18432502
[TBL] [Abstract][Full Text] [Related]
19. Myeloprotective effect of short-course high-dose methylprednisolone treatment before consolidation therapy in children with acute myeloblastic leukemia.
Elmas SA; Cetin M; Tuncer M; Hiçsönmez G
Am J Hematol; 2005 Sep; 80(1):1-5. PubMed ID: 16138333
[TBL] [Abstract][Full Text] [Related]
20. Influence of chemotherapy courses on the rate of bloodstream infections during neutropenia in adult acute myeloid leukaemia.
Kinnunen U; Koistinen P; Ohtonen P; Koskela M; Syrjälä H
Scand J Infect Dis; 2008; 40(8):642-7. PubMed ID: 18979602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]